Abstract 1873P
Background
Patients living with myeloproliferative neoplasms (MPN), including myelofibrosis (MF), polycythaemia vera (PV) and essential thrombocythemia (ET), should engage in self-care behaviours to improve their health. This study aims to preliminary assess self-care behaviours in MPN patients.
Methods
A descriptive cross-sectional study has been conducted in 9 haematology centres in Italy since November 2021. The Italian Association of MPN Patients (AIPAMM) promoted this study. The Self-Care in MyeloProliferative Neoplasms Inventory (SC-MPNI), a 31-item questionnaire measuring self-care behaviours according to the Middle-Range Theory of Self-Care of Chronic Illness, was developed and tested for its content validity. MPN patients were asked to complete a paper-and-pencil questionnaire during their outpatient visit or at home.
Results
Preliminary data from 171 patients (54% male; mean age=58, SD=19) and 5 centres were analysed (45.6% of the expected sample). Participants were living with overt MF (n=51), prefibrotic MF (n=24), PV (n=48) or ET (n=44). Concerning self-care maintenance, the most frequent behaviour was attending all scheduled clinical appointments (M=5.9, SD=0.6), and the least used one was performing activities that improve mental and physical well-being (M=3.1, SD=1.7). Concerning self-care monitoring, the most frequent behaviour was getting blood tests as prescribed by the haematologist (M=5.9, SD=0.5), and the least used one was checking any measurement the healthcare providers recommend (M=4.7, SD=1.4). Concerning self-care management, the most frequent behaviour was accurately reporting symptoms to the healthcare providers during visits to get a comprehensive response (M=5.5, SD=0.9), and the least used one was asking for psychological support to overcome emotional problems (M=2.6, SD=1.5).
Conclusions
This study will contribute to assessing self-care behaviours in patients with MPN. Health professionals should support innovative interventions to promote self-care, which is crucial for MPN patients to reduce cardiovascular events and be medically fit to undergo hematopoietic stem cell transplantation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05